000269866 001__ 269866
000269866 005__ 20240808164406.0
000269866 0247_ $$2pmc$$apmc:PMC11156760
000269866 0247_ $$2doi$$a10.1016/j.biopha.2024.116749
000269866 0247_ $$2pmid$$apmid:38761420
000269866 0247_ $$2ISSN$$a0300-0893
000269866 0247_ $$2ISSN$$a0753-3322
000269866 0247_ $$2ISSN$$a1950-6007
000269866 0247_ $$2altmetric$$aaltmetric:164274238
000269866 037__ $$aDZNE-2024-00692
000269866 041__ $$aEnglish
000269866 082__ $$a610
000269866 1001_ $$aZirpoli, Hylde$$b0
000269866 245__ $$aOmega-3 fatty acid diglyceride emulsions as a novel injectable acute therapeutic in neonatal hypoxic-ischemic brain injury.
000269866 260__ $$aParis [u.a.]$$bElsevier$$c2024
000269866 3367_ $$2DRIVER$$aarticle
000269866 3367_ $$2DataCite$$aOutput Types/Journal article
000269866 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719234921_2991
000269866 3367_ $$2BibTeX$$aARTICLE
000269866 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000269866 3367_ $$00$$2EndNote$$aJournal Article
000269866 500__ $$aISSN 0753-3322 not unique: **2 hits**.
000269866 520__ $$aHypoxic-ischemic encephalopathy (HIE), resulting from a lack of blood flow and oxygen before or during newborn delivery, is a leading cause of cerebral palsy and neurological disability in children. Therapeutic hypothermia (TH), the current standard of care in HIE, is only beneficial in 1 of 7-8 cases. Therefore, there is a critical need for more efficient treatments. We have previously reported that omega-3 (n-3) fatty acids (FA) carried by triglyceride (TG) lipid emulsions provide neuroprotection after experimental hypoxic-ischemic (HI) injury in neonatal mice. Herein, we propose a novel acute therapeutic approach using an n-3 diglyceride (DG) lipid emulsions. Importantly, n-3 DG preparations had much smaller particle size compared to commercially available or lab-made n-3 TG emulsions. We showed that n-3 DG molecules have the advantage of incorporating at substantially higher levels than n-3 TG into an in vitro model of phospholipid membranes. We also observed that n-3 DG after parenteral administration in neonatal mice reaches the bloodstream more rapidly than n-3 TG. Using neonatal HI brain injury models in mice and rats, we found that n-3 DG emulsions provide superior neuroprotection than n-3 TG emulsions or TH in decreasing brain infarct size. Additionally, we found that n-3 DGs attenuate microgliosis and astrogliosis. Thus, n-3 DG emulsions are a superior, promising, and novel therapy for treating HIE.
000269866 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000269866 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000269866 650_7 $$2Other$$adiglycerides
000269866 650_7 $$2Other$$agliosis
000269866 650_7 $$2Other$$ahypoxic-ischemic encephalopathy
000269866 650_7 $$2Other$$alipid emulsion
000269866 650_7 $$2Other$$aneuroprotection
000269866 650_7 $$2Other$$aomega-3 fatty acids
000269866 650_7 $$2NLM Chemicals$$aFatty Acids, Omega-3
000269866 650_7 $$2NLM Chemicals$$aEmulsions
000269866 650_7 $$2NLM Chemicals$$aNeuroprotective Agents
000269866 650_2 $$2MeSH$$aAnimals
000269866 650_2 $$2MeSH$$aHypoxia-Ischemia, Brain: drug therapy
000269866 650_2 $$2MeSH$$aAnimals, Newborn
000269866 650_2 $$2MeSH$$aFatty Acids, Omega-3: administration & dosage
000269866 650_2 $$2MeSH$$aFatty Acids, Omega-3: pharmacology
000269866 650_2 $$2MeSH$$aEmulsions
000269866 650_2 $$2MeSH$$aMice
000269866 650_2 $$2MeSH$$aNeuroprotective Agents: administration & dosage
000269866 650_2 $$2MeSH$$aNeuroprotective Agents: pharmacology
000269866 650_2 $$2MeSH$$aRats
000269866 650_2 $$2MeSH$$aRats, Sprague-Dawley
000269866 650_2 $$2MeSH$$aMice, Inbred C57BL
000269866 650_2 $$2MeSH$$aDisease Models, Animal
000269866 650_2 $$2MeSH$$aMale
000269866 650_2 $$2MeSH$$aBrain: drug effects
000269866 650_2 $$2MeSH$$aBrain: metabolism
000269866 650_2 $$2MeSH$$aBrain: pathology
000269866 7001_ $$0P:(DE-2719)2810557$$aBernis, Maria Eugenia$$b1$$udzne
000269866 7001_ $$0P:(DE-2719)9000732$$aSabir, Hemmen$$b2$$udzne
000269866 7001_ $$aManual Kollareth, Denny Joseph$$b3
000269866 7001_ $$aHamilton, James A$$b4
000269866 7001_ $$aHuang, Nasi$$b5
000269866 7001_ $$aNg, Jesse$$b6
000269866 7001_ $$aSosunov, Sergey A$$b7
000269866 7001_ $$aGaebler, Ben$$b8
000269866 7001_ $$aTen, Vadim S$$b9
000269866 7001_ $$aDeckelbaum, Richard J$$b10
000269866 773__ $$0PERI:(DE-600)392415-4$$a10.1016/j.biopha.2024.116749$$gVol. 175, p. 116749 -$$p116749$$tBiomedicine & pharmacotherapy$$v175$$x0300-0893$$y2024
000269866 8564_ $$uhttps://pub.dzne.de/record/269866/files/DZNE-2024-00692.pdf$$yOpenAccess
000269866 8564_ $$uhttps://pub.dzne.de/record/269866/files/DZNE-2024-00692.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000269866 909CO $$ooai:pub.dzne.de:269866$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000269866 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810557$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000269866 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000269866 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000269866 9141_ $$y2024
000269866 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000269866 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000269866 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000269866 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000269866 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOMED PHARMACOTHER : 2015
000269866 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000269866 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000269866 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000269866 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000269866 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000269866 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000269866 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000269866 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000269866 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000269866 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000269866 9201_ $$0I:(DE-2719)5000032$$kAG Sabir$$lNeonatal Neuroscience$$x0
000269866 980__ $$ajournal
000269866 980__ $$aVDB
000269866 980__ $$aUNRESTRICTED
000269866 980__ $$aI:(DE-2719)5000032
000269866 9801_ $$aFullTexts